Renal Cell Carcinoma: Overview

作者: Ziya Kirkali , Cag Cal

DOI: 10.1007/978-1-84628-738-1_14

关键词: UrologyMedicineRenal cell carcinomaInferior vena cavaRenal pelvis cancerIncidence (epidemiology)Kidney cancerKidneyPapillary renal cell carcinomasChromophobe Renal Cell Carcinoma

摘要: Renal cell carcinoma (RCC) accounts for 3% of all adult cancers. The incidence rates kidney cancer are highest in European and Scandinavian countries North America (1). It is estimated that 36,160 new cases renal pelvis were diagnosed 2005, with an 12,660 resulting deaths the United States (2). There has been a 30% increase last 20 years. Although this increased partly result more widespread aggressive imaging, current reports show real incidence. tumor adults occurring primarily after 5th decade life. occurs one-and-a-half times as often men women (3:2) (3). Childhood RCC uncommon, representing only 2% to 6% tumors children. Bilateral identified 5% patients.

参考文章(95)
M. Detmar, A. M. Dvorak, L. F. Brown, H. F. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. ,vol. 146, pp. 1029- 1039 ,(1995)
Ronald M. Bukowski, Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urologic Oncology. ,vol. 19, pp. 148- 154 ,(2001)
Robert J. Motzer, Robert Amato, Mary Todd, Wen‐J Poo Hwu, Roger Cohen, Jose Baselga, Hyman Muss, Michael Cooper, Richard Yu, Michelle S. Ginsberg, Michael Needle, Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational New Drugs. ,vol. 21, pp. 99- 101 ,(2003) , 10.1023/A:1022928612511
Wayne A. Tompkins, Immunomodulation and Therapeutic Effects of the Oral Use of Interferon-alpha: Mechanism of Action Journal of Interferon & Cytokine Research. ,vol. 19, pp. 817- 828 ,(1999) , 10.1089/107999099313325
Berton Zbar, Hitoshi Kitamura, Takeshi Kishida, Farida Latif, Masahiko Hosaka, Michael I. Lerman, Kelichi Kondo, Yoshinobu Kubota, Masahiro Yao, Soichiro Torigoe, Yoji Nagashima, Taro Shuin, Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Research. ,vol. 54, pp. 2852- 2855 ,(1994)
N. H. Bander, G. Gastl, D. M. Nanus, L. M. Pfeffer, C. L. Finstad, A. P. Albino, Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein Basic and Clinical Research on Renal Cell Carcinoma. ,vol. 50, pp. 115- 120 ,(1992) , 10.1007/978-3-642-76863-7_11
Paul J Hertzog, Jonathan Cebon, Joseph A Trapani, Derek N J Hart, Thomas Luft, Ken C Pang, Elisabeth Thomas, Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells Journal of Immunology. ,vol. 161, pp. 1947- 1953 ,(1998)
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459
G.D. Decker, D.A., Decker, V., Herskovic, A., & Cummings, Brain metastases in patients with renal cell carcinoma: prognosis and treatment. Journal of Clinical Oncology. ,vol. 2, pp. 169- 173 ,(1984) , 10.1200/JCO.1984.2.3.169
Robert A. Figlin, John A. Thompson, Ronald M. Bukowski, Nicholas J. Vogelzang, Andrew C. Novick, Paul Lange, Gary D. Steinberg, Arie S. Belldegrun, Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 17, pp. 2521- 2529 ,(1999) , 10.1200/JCO.1999.17.8.2521